• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics General Medicine Classics

The PARADIGM-HF trial: Valsartan-neprilysin inhibitor vs. enalapril in patients with heart failure [Classic Series]

byShaidah Deghan, MSc. MDandAndrew Cheung, MD MBA
January 28, 2018
in General Medicine Classics, The Classics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. LCZ696, a combination of valsartan with a neprilysin inhibitor, significantly reduced the risk of death from cardiovascular causes and hospitalization due to heart failure when compared to enalapril.

2. There were no significant differences between the two groups in the risk of angioedema, though patients treated with LCZ696 experienced significantly higher rates of symptomatic hypotension.

Original Date of Publication: September 2014

Study Rundown: Millions of North Americans suffer from heart failure. About half of these individuals have heart failure with reduced ejection fraction, and the current standard medication regimen includes an angiotensin converting enzyme (ACE) inhibitor, beta-blocker, and potentially an aldosterone antagonist. In patients who cannot tolerate ACE inhibitors, an angiotensin receptor blocker is used instead. Natriuretic peptides are produced by various tissues and lead to decreased vasoconstriction, sodium retention, and maladaptive remodelling. These peptides are degraded by neprilysin, a neutral endopeptidase, and inhibition of neprilysin had been previously shown to have beneficial hemodynamic effects. Moreover, combining ACE and neprilysin inhibition had been shown to be superior than either treatment alone, though with higher risk of severe angioedema. The risk of angioedema was lower with combination of neprilysin inhibitor and ARB.

The purpose of the Prospective Comparison of ARNI (Angiotensin Receptor-Neprilysin Inhibitor) with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial was to compare the effects of LCZ696, a combination of a neprilysin inhibitor and valsartan, with enalapril in patients with heart failure. Treatment with LCZ696 significantly reduced the risk of death from cardiovascular causes and heart failure hospitalization when compared with enalapril in patients with NYHA class II-IV heart failure and left ventricular ejection fraction ≤35%. This trial demonstrates that treatment with LCZ696 will significantly reduce mortality in patients with heart failure with reduced ejection fraction, and is the first new intervention to do so in many years.

Click to read the study published in NEJM

In-Depth [randomized controlled trial]: This randomized, controlled, double-blind trial involved 8442 patients from 47 countries. Patients were eligible for enrolment if they were ≥18 years of age, NYHA class II-IV symptoms, and left ventricular ejection fraction ≤35%. Exclusion criteria included symptomatic hypotension, systolic blood pressure <100 mmHg at screening, and estimated glomerular filtration rate <30 mL/min/1.73m2. The primary outcome was death from cardiovascular causes or a first hospitalization from heart failure. Secondary outcomes included time to death from any cause, the time to a new onset of atrial fibrillation, and the time to the first occurrence of a first decline in renal function.

RELATED REPORTS

Interatrial shunt device not effective in patients with symptomatic heart failure

Predicted long-term effects of dapagliflozin in heart failure suggest association with improved event-free survival

Hemodynamic-guided management of heart failure may reduce hospitalization rates

Patients in the LCZ696 group experienced significantly lower rates of the primary outcome compared to those on enalapril (HR 0.80; 95%CI 0.73-0.87; p < 0.001). The LCZ696 group experienced significantly less death from cardiovascular causes (HR 0.80; 95%CI 0.71-0.89; p < 0.001) and hospitalization for heart failure (HR 0.79; 95%CI 0.71-0.89; p < 0.001) when compared to the enalapril group. Death from any cause was also significantly lower in the LCZ696 group (HR 0.84; 95%CI 0.76-0.93; p < 0.001). There were no significant differences between the two groups in the number of patients with new-onset atrial fibrillation (p = 0.83) or decline in renal function (p = 0.28). Moreover, there were no significant differences between the groups in the risk of angioedema, though patients on LCZ696 experienced significantly higher rates of symptomatic hypotension (p < 0.001).

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: congestive heart failureparadigm hf
Previous Post

HIV exposure and infection affect neurodevelopmental outcomes in young children

Next Post

Greater rates of mortality linked to infants at risk for maltreatment

RelatedReports

30-Day mortality decreased in UK pediatric cardiac surgery from 2000-2010
Cardiology

Interatrial shunt device not effective in patients with symptomatic heart failure

March 29, 2022
Long-term outcomes for off-pump and on-pump CABG are similar
Cardiology

Predicted long-term effects of dapagliflozin in heart failure suggest association with improved event-free survival

November 8, 2021
Rilonacept may lower pericarditis recurrence in patients with relapsing pericarditis
Cardiology

Hemodynamic-guided management of heart failure may reduce hospitalization rates

September 22, 2021
Rilonacept may lower pericarditis recurrence in patients with relapsing pericarditis
Cardiology

Relative risk of heart failure from traditional risk factors is greater in younger than in older adults

April 23, 2021
Next Post

Greater rates of mortality linked to infants at risk for maltreatment

Free alternatives comparable to Mini-Mental State Examination

2 Minute Medicine Rewind January 29, 2018

Live attenuated vaccine less effective in recent influenza season

Viral respiratory infections associated with increased risk of acute myocardial infarction

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Pelvic lymph node radiotherapy and androgen deprivation therapy augment progression-free status following prostatectomy
  • Operating the day after performing surgery the previous night not associated with adverse patient outcomes
  • Gratitude-focused writing may improve mental wellness during periods of chronic stress
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.